Heron Therapeutics Inc
HRTX1.340USD
+0.040+3.08%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
245.65MMarket Cap
LossP/E TTM
More Details of Heron Therapeutics Inc Company
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.
Heron Therapeutics Inc Info
Ticker SymbolHRTX
Company nameHeron Therapeutics Inc
IPO dateAug 26, 1987
CEOCollard (Craig Alexander)
Number of employees122
Security typeOrdinary Share
Fiscal year-endAug 26
Address4242 Campus Point Court, Suite 200
CityCARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582514400
Websitehttps://www.herontx.com/
Ticker SymbolHRTX
IPO dateAug 26, 1987
CEOCollard (Craig Alexander)
Company Executives of Heron Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
504.19K
+10.66%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
179.79K
+9.48%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
166.20K
+10.33%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Mr. Adam Morgan
Mr. Adam Morgan
Chairman of the Board
Chairman of the Board
32.89K
+19.94%
Mr. Michael Kaseta
Mr. Michael Kaseta
Independent Director
Independent Director
2.37K
-95.76%
Mr. Mark Hensley
Mr. Mark Hensley
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Tom Cusack ,
Mr. Tom Cusack ,
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Craig Alexander Collard
Mr. Craig Alexander Collard
Chief Executive Officer, Director
Chief Executive Officer, Director
504.19K
+10.66%
Ms. Ira Duarte
Ms. Ira Duarte
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
179.79K
+9.48%
Dr. William P. (Bill) Forbes
Dr. William P. (Bill) Forbes
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
166.20K
+10.33%
Dr. Sharmila Dissanaike, M.D.
Dr. Sharmila Dissanaike, M.D.
Independent Director
Independent Director
68.45K
-3.44%
Mr. Christian Waage
Mr. Christian Waage
Independent Director
Independent Director
66.18K
+26.70%
Mr. Craig A. Johnson
Mr. Craig A. Johnson
Lead Independent Director
Lead Independent Director
65.82K
-5.73%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
CINVANTI
24.14M
64.90%
ZYNRELEF
8.19M
22.01%
APONVIE
2.46M
6.62%
SUSTOL
2.40M
6.46%
By RegionUSD
Name
Revenue
Proportion
United States
37.20M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CINVANTI
24.14M
64.90%
ZYNRELEF
8.19M
22.01%
APONVIE
2.46M
6.62%
SUSTOL
2.40M
6.46%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
16.39%
Adage Capital Management, L.P.
5.58%
Clearline Capital LP
5.30%
BlackRock Institutional Trust Company, N.A.
4.95%
Velan Capital Investment Management LP
4.77%
Other
63.01%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
16.39%
Adage Capital Management, L.P.
5.58%
Clearline Capital LP
5.30%
BlackRock Institutional Trust Company, N.A.
4.95%
Velan Capital Investment Management LP
4.77%
Other
63.01%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.25%
Investment Advisor
21.56%
Investment Advisor/Hedge Fund
17.27%
Research Firm
4.48%
Pension Fund
1.41%
Individual Investor
0.65%
Private Equity
0.26%
Bank and Trust
0.10%
Family Office
0.04%
Other
14.99%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
340
135.17M
76.83%
-19.43M
2025Q2
352
128.42M
84.17%
-20.15M
2025Q1
384
126.94M
83.22%
-22.20M
2024Q4
390
118.52M
78.10%
-45.51M
2024Q3
400
125.21M
82.85%
-42.71M
2024Q2
402
132.96M
88.55%
-36.75M
2024Q1
402
122.65M
81.87%
-45.18M
2023Q4
413
115.58M
77.36%
-37.11M
2023Q3
417
122.12M
87.17%
-25.94M
2023Q2
428
102.54M
85.75%
-39.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
29.10M
15.87%
+2.39M
+8.94%
Aug 08, 2025
Adage Capital Management, L.P.
7.85M
4.28%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.13M
4.98%
+1.33M
+17.12%
Jun 30, 2025
Velan Capital Investment Management LP
6.99M
3.81%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
8.47M
4.62%
+245.88K
+2.99%
Jun 30, 2025
Palisade Capital Management, LLC
5.09M
2.77%
-200.03K
-3.78%
Jun 30, 2025
Tejara Capital Ltd.
4.52M
2.46%
-59.99K
-1.31%
Jun 30, 2025
State Street Investment Management (US)
3.46M
1.89%
+208.36K
+6.40%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.46%
iShares Micro-Cap ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Vanguard US Momentum Factor ETF
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.46%
iShares Micro-Cap ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Vanguard US Momentum Factor ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Heron Therapeutics Inc?
The top five shareholders of Heron Therapeutics Inc are:
Rubric Capital Management LP holds 29.10M shares, accounting for 15.87% of the total shares.
Adage Capital Management, L.P. holds 7.85M shares, accounting for 4.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.13M shares, accounting for 4.98% of the total shares.
Velan Capital Investment Management LP holds 6.99M shares, accounting for 3.81% of the total shares.
The Vanguard Group, Inc. holds 8.47M shares, accounting for 4.62% of the total shares.
Rubric Capital Management LP holds 29.10M shares, accounting for 15.87% of the total shares.
Adage Capital Management, L.P. holds 7.85M shares, accounting for 4.28% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.13M shares, accounting for 4.98% of the total shares.
Velan Capital Investment Management LP holds 6.99M shares, accounting for 3.81% of the total shares.
The Vanguard Group, Inc. holds 8.47M shares, accounting for 4.62% of the total shares.
What are the top three shareholder types of Heron Therapeutics Inc?
The top three shareholder types of Heron Therapeutics Inc are:
Rubric Capital Management LP
Adage Capital Management, L.P.
Clearline Capital LP
Rubric Capital Management LP
Adage Capital Management, L.P.
Clearline Capital LP
How many institutions hold shares of Heron Therapeutics Inc (HRTX)?
As of 2025Q3, 340 institutions hold shares of Heron Therapeutics Inc, with a combined market value of approximately 135.17M, accounting for 76.83% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.34%.
What is the biggest source of revenue for Heron Therapeutics Inc?
In FY2025Q2, the CINVANTI business generated the highest revenue for Heron Therapeutics Inc, amounting to 24.14M and accounting for 64.90% of total revenue.
